Virtus ETF Advisers’s Kite Pharma, Inc. KITE Stock Holding History

Virtus ETF Advisers’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-3,340	Closed	-$346K	–	164
2017 Q2	$346K	Sell	3,340 -2,537	-43%	-$207K	0.05%	88
2017 Q1	$461K	Buy	5,877 +564	+11%	+$34.9K	0.08%	106
2016 Q4	$238K	Buy	5,313 +424	+9%	+$20.8K	0.07%	157
2016 Q3	$273K	Hold	4,889	–	–	0.13%	109
2016 Q2	$244K	Buy	4,889 +949	+24%	+$46.6K	0.18%	97
2016 Q1	$181K	Buy	+3,940	New	+$191K	0.25%	99

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Virtus ETF Advisers's KITE Position: Q3 2017 in Review

Virtus ETF Advisers sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 3,340 shares — an estimated $346K sold.

Virtus ETF Advisers first reported a position in KITE in Q1 2016 and held it in 6 quarters. The position peaked at $461K in Q1 2017. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Virtus ETF Advisers reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Virtus ETF Advisers sold 3,340 Kite Pharma, Inc. shares in Q3 2017, an estimated $346K.
Virtus ETF Advisers first reported a position in Kite Pharma, Inc. in Q1 2016 and held it in 6 quarters.
Virtus ETF Advisers's Kite Pharma, Inc. position peaked at $461K in Q1 2017.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Virtus ETF Advisers's 13F filing for Q3 2017, filed 14 Nov 2017.